Trastuzumab deruxtecan (DS-8201a) is an antibody-drug conjugate used for the treatment of metastatic HER2+ breast cancer that is refractory to anti-HER2 therapy such as T-DM1, however, there is a lack of knowledge on acquired or innate resistance to the drug.

Approximately 20,000 patients diagnosed with non-Hodgkin lymphomas died in 2022 despite current treatments; 30-40% of these cases involved diffuse large B-cell lymphoma (DLBCL). Monoallelic mutations in histone acetyltransferases (HATs) occur in over 39% of germinal center DLBCLs. Activation of intact wild-type alleles offers an opportunity to overcome the mutated allele.

Researchers from Taipei Medical University presented the discovery of novel store-operated calcium channel (SOC) inhibitors as potential anticancer candidates. Synthesis and optimization of a series of difluorobenzamide derivatives led to the discovery of MPT-0M004 as the lead candidate with promising SOC inhibitory activity. In vitro, both migration and invasion of colorectal cancer cells were significantly suppressed after 48 hours of treatment with MPT-0M004, with the growth inhibitory effect of the compound being similar to that seen for the reference SOC inhibitor.

Affimed NV has received clearance of a clinical trial application (CTA) by the French National Agency for the Safety of Medicines and Health Products (ANSM) for a phase I study of AFM-28 (AFM28-101) in CD123-positive relapsed or refractory acute myeloid leukemia (AML).

The FDA has cleared an IND for a clinical trial in the U.S. of NBL-020, a fully human antibody drug independently developed by CSPC Pharmaceutical Group Ltd.'s subsidiary Novarock Biotherapeutics Ltd., for the treatment of advanced solid tumors.